Allogeneic CAR19 cells clear ALL.
Chimeric antigen receptor T cells redirected to CD19 (chimeric antigen receptor [CAR19]) show great promise in the clinic to treat refractory CD19+ acute lymphoblastic leukemia (ALL). However, production of autologous CAR19 cells from these patients can be difficult as patients frequently have T-cell dysfunction, due to disease and/or treatment-related effects. In this issue of Blood, Jacoby et al1 addressed this by exploring whether allogeneic donor CAR19 cells could be used to treat ALL-bearing mice using a minor mismatch bone marrow transplant model.